BACKGROUND: Apoptosis-stimulating protein of p53 (ASPP) family members can stimulate the apoptotic function of p53 but have no impact on its cell cycle arrest function. MATERIAL AND METHODS: The expression pattern of the ASPP family consisting of ASPP1, ASPP2, and iASPP was examined by immunohistochemistry in 45 formalin-fixed and paraffin-embedded endometrial endometrioid adenocarcinoma (EEA) specimens and 26 normal endometrial tissue (NET) samples. RESULTS: The expression rates of ASPP1 and ASPP2 in EEA were significantly lower than those in NET (p < 0.05). However, the iASPP expression rate in EEA was statistically higher in contrast to NET (p < 0.05). Expression of ASPP1 and iASPP in EEA had no correlation with any clinicopathological features (p > 0.05). iASPP was associated with grade, invasion, and lymph node metastasis (p < 0.05). CONCLUSIONS: It is a novel finding that the expression pattern of the ASPP family members has respective pathological and clinical implications in EEA, and iASPP might be a candidate target for EEA therapy.
BACKGROUND: Apoptosis-stimulating protein of p53 (ASPP) family members can stimulate the apoptotic function of p53 but have no impact on its cell cycle arrest function. MATERIAL AND METHODS: The expression pattern of the ASPP family consisting of ASPP1, ASPP2, and iASPP was examined by immunohistochemistry in 45 formalin-fixed and paraffin-embedded endometrial endometrioid adenocarcinoma (EEA) specimens and 26 normal endometrial tissue (NET) samples. RESULTS: The expression rates of ASPP1 and ASPP2 in EEA were significantly lower than those in NET (p < 0.05). However, the iASPP expression rate in EEA was statistically higher in contrast to NET (p < 0.05). Expression of ASPP1 and iASPP in EEA had no correlation with any clinicopathological features (p > 0.05). iASPP was associated with grade, invasion, and lymph node metastasis (p < 0.05). CONCLUSIONS: It is a novel finding that the expression pattern of the ASPP family members has respective pathological and clinical implications in EEA, and iASPP might be a candidate target for EEA therapy.
Authors: Yeyun Zhou; Robyn Millott; Hyeong Jin Kim; Shiyun Peng; Ross A Edwards; Tamara Skene-Arnold; Michal Hammel; Susan P Lees-Miller; John A Tainer; Charles F B Holmes; J N Mark Glover Journal: Structure Date: 2019-08-08 Impact factor: 5.006
Authors: Yihua Wang; Fangfang Bu; Christophe Royer; Sébastien Serres; James R Larkin; Manuel Sarmiento Soto; Nicola R Sibson; Victoria Salter; Florian Fritzsche; Casmir Turnquist; Sofia Koch; Jaroslav Zak; Shan Zhong; Guobin Wu; Anmin Liang; Patricia A Olofsen; Holger Moch; David C Hancock; Julian Downward; Robert D Goldin; Jian Zhao; Xin Tong; Yajun Guo; Xin Lu Journal: Nat Cell Biol Date: 2014-10-26 Impact factor: 28.824